Antibody-Drug Conjugates in Triple Negative Breast Cancer
Clinical Breast Cancer, cilt.24, sa.3, ss.163-174, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 24 Sayı: 3
- Basım Tarihi: 2024
- Doi Numarası: 10.1016/j.clbc.2024.01.008
- Dergi Adı: Clinical Breast Cancer
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.163-174
- Anahtar Kelimeler: TNBC, ADC, Trop-2, Sacituzumab govitecan, Trastuzumab deruxtecan
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer. It is a heterogeneous breast cancer subtype with a poor prognosis. Given these negative features, there is a need for new treatment options beyond conventional chemotherapy in both the early stage and palliative setting. Impressive results have been reported with antibody-drug conjugates (ADCs) that link a cytotoxic payload to a monoclonal antibody, such as sacituzumab govitecan and trastuzumab deruxtecan, in the metastatic stage. The focus of this review is to discuss completed and ongoing trials involving ADCs in TNBC.